Sector: Health Care
CORCEPT THERAPEUTICS INC · Meeting: May 21, 2026
Directors FOR
8
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Election of Directors
Corcept's 3-year stock return of +104.9% outpaces the XBI (SPDR S&P Biotech ETF) return of +71.4% by +33.5 percentage points, well below the 65-percentage-point trigger threshold required for a strong-positive-TSR company, so no TSR-based concern applies; Dr. Belanoff is the founding CEO with deep industry expertise and no overboarding or attendance issues.
The 3-year TSR gap of +33.5pp versus XBI (SPDR S&P Biotech ETF) does not reach the 65pp trigger threshold for a company with strong positive absolute returns; Mr. Wilson has served as Chairman since 1999 with relevant biotechnology executive and board experience and no overboarding concerns flagged.
The TSR trigger does not apply given Corcept's +33.5pp outperformance versus XBI (SPDR S&P Biotech ETF) is below the 65pp threshold; Mr. Alton brings extensive pharmaceutical executive experience in legal, regulatory and medical affairs and serves on the Audit and Compensation Committees with no independence, attendance, or overboarding concerns.
The TSR trigger does not fire as Corcept's 3-year outperformance of XBI (SPDR S&P Biotech ETF) is +33.5pp, below the 65pp threshold; Mr. Baker is a long-tenured venture capitalist with finance and strategic transaction expertise and no overboarding or attendance concerns.
The TSR trigger does not apply given the +33.5pp gap versus XBI (SPDR S&P Biotech ETF) is below the 65pp strong-positive-TSR threshold; Mr. Mahoney has broad experience in healthcare and pharmaceutical operations and chairs the Compensation Committee with no independence or attendance concerns.
The TSR trigger does not apply; Mr. Murray joined in June 2021 and brings investment banking and biotechnology finance expertise, serves on the Audit Committee, and has no overboarding or attendance concerns.
The TSR trigger does not apply given Corcept's +33.5pp 3-year outperformance of XBI (SPDR S&P Biotech ETF) is well below the 65pp threshold; Ms. Park brings deep pharmaceutical commercial and marketing experience and chairs the Corporate Governance and Nominating Committee with no independence, attendance, or overboarding concerns.
The TSR trigger does not fire; Mr. Swisher brings extensive pharmaceutical industry executive experience including as former CEO and COO of public biotech companies and serves on the Compensation Committee with no overboarding or attendance concerns.
All eight director nominees receive a FOR vote. Corcept's 3-year stock return of +104.9% exceeds the XBI (SPDR S&P Biotech ETF) return of +71.4% by +33.5 percentage points, which is well below the 65-percentage-point underperformance threshold required to trigger a AGAINST vote for companies with strong positive absolute returns. No directors are overboarded, all attended at least 75% of meetings, and all independent directors serve on appropriate committees with no independence concerns.
CEO
Joseph K. Belanoff, M.D.
Total Comp
$15,303,551
Prior Support
94%%
CEO total compensation of $15,303,551 is dominated by stock option awards ($12,907,718), meaning the vast majority of pay is variable and tied to long-term stock price appreciation — options only pay off if the share price rises, which strongly aligns the CEO's interests with shareholders. Corcept's 3-year stock return of +104.9% outpaced the XBI (SPDR S&P Biotech ETF) by +33.5 percentage points, confirming that above-benchmark incentive pay is supported by strong stock performance relative to biotech peers. Prior-year shareholder support was 94%, reflecting broad investor confidence in the pay program, and the company achieved meaningful milestones in 2025 including revenue growth to $761 million and FDA NDA submission for a key oncology drug.
Auditor
Ernst & Young LLP
Tenure
N/A
Audit Fees
$2,846,000
Non-Audit Fees
$151,000
Non-audit fees (tax advisory and compliance services totaling $151,000) represent only about 5.3% of audit fees ($2,846,000), far below the 50% threshold that would raise independence concerns; Ernst & Young is a Big 4 firm appropriate for Corcept's ~$4.9B market cap; auditor tenure is not disclosed in the proxy so the tenure trigger cannot fire, and no material restatements are noted.
The 2026 Corcept Therapeutics annual meeting ballot contains four proposals: election of eight directors (all receiving FOR votes given strong 3-year TSR outperformance versus XBI), ratification of Ernst & Young as auditor (FOR given a very low non-audit fee ratio of ~5%), an advisory vote on executive pay (FOR given 94% prior-year support, option-heavy pay structure, and strong biotech peer outperformance), and an equity plan amendment to add 8 million new shares (outside current policy scope). No stockholder proposals were submitted for this meeting.
